Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Paclitaxel, Trastuzumab, and Lapatinib in Early HER2+ Breast Cancer
NCT01827163Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2013
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in HER2-positive breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of Participants Who Are Able to Complete THL Without a Dose Delay or Reduction, Grade 3 or Greater QTc Prolongation at 1 year. Started Apr 2013; status: completed.
02
Drugs
lapatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01827163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01827163.